REGISTER
Longlists and Nominations Announced for Drug Categories of the Inaugural Huashan Awards

Following quantitative evaluation and expert review, the longlist and nomination results for the drug categories of the Inaugural Huashan Awards have been officially announced.

Jointly initiated by MedJ and Tonacea, the Huashan Awards aim to identify value-based benchmarks in China’s innovative drug landscape through data-driven assessment, independent expert review, and international evaluation standards.

The Huashan Awards include two drug-focused categories: Best Clinical Value Medication and Best Breakthrough Medication. Based on predefined quantitative indicators, industry data were extracted from publicly available and reliable databases for analysis and scoring. Shortlisted drugs were then reviewed and voted on by the Drug Expert Review Committee before being submitted to the Management Committee for final evaluation.

Final award results will be announced on January 17th at the Huashan Awards Ceremony and the 2026 China Innovative Drug New Year Outlook Conference.

Best Clinical Value Medication

This award recognizes innovative drugs approved in China within the past three years that have also been launched in the United States or Europe. Eligible products must be First-in-Class (FIC) or potential Best-in-Class (BIC), already applied in clinical practice, and demonstrate significant clinical and social value.

Nominations Medications:

  1. Enhertu® (fam-trastuzumab deruxtecan-nxki) — Daiichi Sankyo / AstraZeneca China

  2. Mounjaro® (tirzepatide) — Eli Lilly China

  3. Rybrevant® (amivantamab-vmjw) — Johnson & Johnson China / Genmab

  4. Leqembi® (lecanemab irmb) — Eisai / Biogen

  5. Camzyos® (mavacamten) — Bristol Myers Squibb China

  6. Sunlenca® (lenacapavir) — Gilead Sciences

Included in the Longlist but Not Nominated:

  • Vanrafia® (atrasentan)

  • Ziihera® (zanidatamab-hrii)

  • Leqvio® (inclisiran)

*Drugs that have already been nominated are not listed again.

Best Breakthrough Medication

This award focuses on innovative drugs approved in China within the past three years that demonstrate major technological breakthroughs, including novel targets, mechanisms of action, molecular formats, or delivery technologies. Breakthrough innovations in rare diseases and vaccines are also emphasized.

Nominations Medications:

  1. Qfitlia® (Fitusiran) — Sanofi

  2. Vyvgart® Hytrulo (Efgartigimod Alfa-fcab Iinjection) — Zai Lab / argenx

  3. ZEGFROVY® (Sunvozertinib) — Dizal Pharma

  4. KarXT® (Cobenfy,xanomeline and trospium chloride) — Zai Lab / Bristol Myers Squibb China

  5. TALVEY® (talquetamab-tgvs) — Johnson & Johnson China / Genmab

  6. Fabhalta® (iptacopan) — Novartis China

Included in the Longlist but Not Nominated:

  • Livtencity®(Maribavir)

  • Wakix® (Pitolisant)

  • Fu Mainin® (Luvometinib)

*Drugs that have already been nominated are not listed again.

0
0
Loading